Would you consider omitting concurrent chemoradiation for a patient with stage III EGFR-mutant NSCLC and initiating treatment with osimertinib instead?

No. Osimertinib alone is a palliative treatment with limited durability, which is not appropriate as first-line therapy for a patient who is interested in and eligible for definitive treatment. While the outcomes of the control arm of chemoradiotherapy without osimertinib in the LAURA trial were certainly disappointing, the standard of care is now the experimental arm of chemoradiotherapy followed by osimertinib. There is no evidence that omitting chemoradiotherapy in favor of osimertinib monoth...

I would not. The results generated in the winning arm of the LAURA trial were not achieved with osimertinib alone. It was achieved with CRT followed by osimertinib.